Background: The outcome of patients with chronic hepatitis C virus infection
| INTRODUCTION
Infection with the hepatitis C virus (HCV) is present in more than 184 million people worldwide and is responsible for the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma, besides being the leading indication for liver transplantation in Western countries. 1, 2 The recent advent of all-oral and highly effective directacting antivirals (DAAs) therapy has revolutionized the treatment paradigm of chronic hepatitis C. 3 In fact, while in the past interferon treatment of patients with advanced, compensated liver disease-when not contraindicated-was burdened by a high incidence of treatment-related adverse events and was associated with low rates of sustained virological response (SVR), the most recent DAA treatment is able to obtain very high SVR rates even in patients with mildly decompensated disease and has a quite favourable safety profile. 4, 5 This paradigm shift has made possible (successful) treatment of patients where treatment was often unfeasible and has thus permitted to explore the potential benefit of viral clearance even in patients with clinical features of advanced liver disease, allowing to assess portal hypertension-related modifications as well as amelioration of liver function in large cohorts of patients. 9, 10 For instance, some studies assessed modifications in global prognostic scores, such as the Model for End-stage Liver Disease (MELD), in patients with mainly decompensated liver disease and showed a short-term improvement in approximately 50% of patients following cure of HCV infection, while other studies showed improvement in portal hypertension and, lastly, some others provided evidence that SVR may be associated with delisting of patients previously listed for liver transplantation. 8, 9 However, few studies evaluated the occurrence of liver fibrosis modifications-as assessed by means of transient elastography or other ultrasonography-based techniques-and in these studies, liver stiffness improvement was mainly evaluated in the short-term after treatment response, mostly in heterogeneous cohorts including patients with no fibrosis and cirrhosis, or patients with cofactors for liver disease progression where the identification of potential improvement in liver function putatively associated with modifications of liver stiffness was less easily identifiable. 16, 17 Therefore, we planned this study with the aim to assess modifications in liver stiffness, as assessed by transient elastography, as well as longitudinal modifications in biochemical and clinical parameters suggestive of liver dysfunction and portal hypertension in a cohort of patients with advanced, compensated chronic HCV-related liver disease who had achieved a SVR to DAA treatment and who had at least a 1-year follow-up after the end of treatment. We surmised that, as compared to previous studies on the same topic, a longer follow-up might capture potential modifications of liver stiffness that are unrelated to the simple decrease in liver necro-inflammatory activity, but rather associated with improvement in liver architecture and function.
| METHODS

| Patients
This is a prospective study aimed at assessing the clinical, biochemical and instrumental outcome of patients with advanced, compensated chronic HCV-related liver disease who had achieved a SVR to an interferon-free DAA treatment carried out at our Institution (Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy) and who had at least 1-year follow-up. Criteria for inclusion in this study were the achievement of SVR to interferon-free DAA treatment in patients with advanced fibrosis and cirrhosis (at least F3 fibrosis stage according to METAVIR), and available follow-up after the end of antiviral treatment of at least 52 weeks. 22 Exclusion criteria were the presence of decompensated liver disease, co-infection with hepatitis B virus or with human immunodeficiency virus, active hepatocellular carcinoma (HCC) at baseline and history of congestive heart failure. In all, between January 2015 and December 2016, 52 patients had the characteristics for being included into this study and therefore represent this study cohort. In the same period, two more patients with the same characteristics were treated with DAAs and did not reach the SVR (one relapse, one primary nonresponse likely due to nonadherence), therefore resulting in an intention-to-treat SVR rate of 96.3% (52/54 patients). All patients underwent complete biochemical work-up at baseline, at the end of treatment and at the end of follow-up, while liver ultrasonography and spleen bi-polar diameter measurement as well as liver stiffness measurement were carried out at baseline and at the end of follow-up.
The study procedures were all part of the routine evaluation of patients at our Unit and therefore a dedicated ethic committee approval was waived, although informed consent for procedures, antiviral treatment and use of data was obtained from all patients as per Institutional guidelines.
| Antiviral therapy
All patients received an interferon-free DAA therapy, with or without ribavirin, for 12 or 24 weeks, according to the availability of antiviral drugs in our Country at the time of the study and to the treatment guidelines issued by the National Association. More in detail, patients were treated following the National guidelines and according to the Italian National Health service criteria. 23, 24 Briefly, when antiviral therapy with DAAs was initially introduced in Italy, treatment was reimbursed only for patients with advanced fibrosis (METAVIR F3), patients with cirrhosis, patients with extrahepatic manifestation of HCV (eg, symptomatic cryoglobulinaemia), patients on the liver transplant waiting list and transplanted patients. Before treatment, positivity of HCV infection and HCV RNA levels was determined in all patients using the COBAS AmpliPrep/COBAS TaqMan HCV Test (Roche Diagnostics, Mannheim, Germany; lower limit of detection: 15 IU/mL). Table S1 shows the main viral and treatment-related characteristics of the study population: 23 patients (44.2%) had high viraemia (ie, serum HCV RNA >800 000 IU/ mL), approximately one-third of the population (n = 18, 34.6%) was treatment-experienced, and among them, four patients (22.2%) had previously been treated with pegylated interferon and first-generation DAAs. Current DAA treatment was carried out mainly with sofosbuvir-based regimens (n = 49, 94.2%), and 32 patients (61.5%) were treated with a ribavirin-containing schedule. Median treatment duration was 12 weeks, with 11 patients (21.2%) treated for 24 weeks. We considered SVR as undetectable serum HCV RNA (lower limit <15 U/mL) 12 weeks after the end of treatment. None of the patients experienced side effects during antiviral therapy that were related to DAA, and in particular, none of the patients who were coprescribed ribavirin needed dose reduction or erythropoietin support, or blood transfusions.
| Laboratory tests and noninvasive indices of liver fibrosis
Laboratory tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, creatinine levels, international normalized ratio (INR) and platelet count, were performed at baseline, at the end of treatment, and at the end of follow-up. Body mass index (BMI, kg/m 2 ) was calculated in all patients at baseline, and overweight and obesity were defined as BMI 25.0 to <30.0 and ≥30.0, respectively. We calculated the AST-to-ALT ratio (AST/ALT ratio), the AST/platelet ratio index (APRI) score (AST [ 
| Transient elastography and abdominal ultrasonography
Liver stiffness was assessed at baseline and at the end of follow-up by means of transient elastography using a standard M probe (FibroScan; Echosens, Paris, France). Briefly, patients who were fasted for at least 6 hours were placed in a supine position with their right arm lifted and stiffness measurement was obtained from the right lobe of the liver positioning the probe through the intercostal spaces. Transient elastography results for each patient, reported in kilopascal (kPa), were calculated as the median of a minimum of ten consecutive measurements, and only examinations with a success rate ≥60% and interquartile range/mean value ≤30% were included, according to the current standards. 33, 34 An inferior cut-off of 9.9 kpa was used to select patient inclusion in the study, according to previously published reports by the Associazione Italiana per lo Studio del Fegato and the Italian National Health Service criteria for reimbursing antiviral treatment at the time of the study. 23,24, 33 The elastography results compatible with the presence (ie, ≥21.0 kPa) or absence (ie, <13.6 kPa) of clinically significant portal hypertension were obtained from the current literature. 34, 35 Lastly, "clinically significant" reduction in liver stiffness was defined as an decrease in stiffness value of at least 30%, as reported in the literature on the basis of an arbitrary cutoff. 36 Spleen ultrasonography was carried out at baseline and at the end of follow-up by an experienced operator, and maximum spleen bi-polar diameter, expressed in mm, was assessed by means of ultrasound scan. Splenomegaly was defined as a spleen bi-polar diameter >120 mm. As previously reported, the coefficient of variation for repeated measurements of this parameter was <2%. 37 Both operators performing liver stiffness evaluation and liver ultrasound were unaware of the patients status and of their baseline result. HCC was diagnosed according to published national guidelines. 38 
| Statistical analysis
Continuous data are shown as median with 25th and 75th percentiles, and categorical variables are shown as absolute value and percentage. Comparison between data at two study time points was carried out using the wilcoxon test for paired samples, while comparison among various time points was carried out using the friedman test. Correlation between baseline alanine aminotransferase levels and baseline liver stiffness measurement was carried out using the pearson correlation coefficient (r). Comparison of categorical variables was carried out using fisher's exact test. The accuracy (c-index) of baseline liver stiffness index in predicting liver stiffness modification at follow-up was assessed by means of receiver operating characteristic (roc) curve. Reporting of the study conforms to strobe statement. 39 
| RESULTS
The main demographic and biological characteristics of the study population are shown in Table 1 (7) (8) (9) , and only one patient (1.9%) had a MELD score ≥15. One patient (1.9%) had a history of HCC that was cured 31 months before antiviral therapy, with no evidence of tumour recurrence at the time of inclusion.
| Evaluation of absolute liver stiffness modifications
After a median follow-up of 60 weeks (56-72 weeks) following the end of treatment, median liver stiffness significantly decreased from a baseline value of 15.2 kPa (11.2-21.0) to a value of 9.3 kPa (6.7-16.8) at the end of followup (P < 0.0001), with an absolute median decrease in liver stiffness of −4.8 kPa (−9.0 to −2.5) and a relative median decrease of −39.4% (−56.0 to −17.9). Figure 1A shows the individual modifications in liver stiffness, while median stiffness at baseline and at the end of follow-up in the whole cohort is shown in Figure 1B .
Overall, absolute liver stiffness values decreased in 45 patients (86.6%), were unmodified in two patients (3.8%) and increased in five patients (9.6%). The accuracy of baseline absolute liver stiffness value in predicting worsening or no modification of absolute liver stiffness at the end of follow-up was poor (c-index = 0.573; 0.428-0.709). No correlation was observed between baseline ALT levels and liver stiffness (r = −0.004, P = 0.978. Figure S1 ). Lastly, we observed no difference in stiffness modification according to the presence of baseline ALT or AST above the upper limit of normal (ie, 40 IU/L).
| Evaluation of liver stiffness modifications according to baseline METAVIR fibrosis scores
At baseline, 25 patients (48.1%) and 27 patients (51.9%) had a liver stiffness value compatible with a METAVIR F3 and F4 stage, respectively, while at the end of follow-up, liver stiffness values were compatible with a METAVIR stage F4 in 17 patients (32.6%), F3 in eight patients (15.4%), F2 in seven patients (13.5%), F1 in 13 patients (25.0%) and F0 in seven patients (13.5%). Figure 2 shows the distribution of the METAVIR fibrosis stages in the study cohort according to liver stiffness cut-offs at baseline (F4 and F3) and at the end of follow-up. Overall, according to liver stiffness cut-offs, METAVIR fibrosis stage decreased in 31 patients (59.6%), remained unchanged in 19 patients (36.6%) and increased in two patients (3.8%). Although the proportional decrease in liver stiffness was greater in patients with baseline F4 stage (−44.1%) as compared to those with baseline F3 stage (−36.4%), more patients who were staged F3 at baseline showed a decrease in METAVIR stage as compared to patients with a baseline F4 stage (P = 0.026).
Lastly, a clinically significant decrease in liver stiffness, defined as a decrease in at least 30% compared to baseline, according to literature, was observed in 31 patients (59.9%) with a similar distribution in patients with baseline F4 (n = 16, 59.2%) and F3 (n = 15, 60.0%).
| Modification in indirect indices of liver fibrosis and clinical variables
APRI score progressively and significantly decreased from baseline to the end of treatment, up to the end of follow-up (P < 0.0001, Figure S2A ). At this point, significantly fewer patients had an APRI score >1.0 (n = 4, 7.7%) as compared to baseline (n = 25, 48.1%; P < 0.0001). FIB-4 values were higher at baseline as compared to values calculated at the end of treatment and at the end of follow-up (P = 0.025, Figure S2B ). We observed a trend towards a lower proportion of patients with a FIB-4 value >3.25 (P = 0.056) at the end of follow-up (n = 11, 21.2%) as compared to baseline (n = 21, 40.4%). Aminotransferases significantly decreased from baseline to the end of treatment, showing a plateau from this latter time point to the end of follow-up (P < 0.0001). We observed a progressive increase in serum albumin at the end of follow-up as compared to the end of treatment and baseline (P = 0.010), while we observed a concomitant decrease in serum bilirubin (P = 0.011) as well as in gamma globulin (P = 0.0003) from baseline to the end of treatment, that was less pronounced at the end of follow-up. Median INR as well as serum creatinine showed no modifications at the various study time points (Table 2) were observed in 28 (53.8%) and two patients (3.8%), respectively, while these figures were 22 (42.3%) and none (0%), respectively, at the end of follow-up. We observed a statistically significant decrease (P = 0.0009) in spleen bipolar diameter from baseline (120 mm ) to the end of follow-up (110 mm [100-120]); moreover, the proportion of patients with splenomegaly (ie, spleen bi-polar diameter >120 mm) showed a decreasing trend (P = 0.085) from baseline (n = 20, 38.5%) to the end of follow-up (n = 11, 21.1%).
| Modifications in liver stiffness and clinical events
A liver stiffness value suggestive of the presence (ie, ≥21.0 kPa) or absence (ie, <13.6 kPa) of clinically significant portal hypertension was found in 13 (25.0%) and 22 patients (42.3%) at baseline and in seven (13.5%) and 35 patients (67.3%) at follow-up (P = 0.037, Figure 3) . Among the seven patients with liver stiffness suggestive of the presence of clinically significant portal hypertension at follow-up, three patients already had this characteristic at baseline, three patients had a liver stiffness value between 13.6 and 20.9 kPa, and only one patient had a liver stiffness value <13.6 kPa at baseline. During follow-up, none of the patients developed liver decompensation, and four patients (7.7%) developed HCC after a median of 98 weeks from the beginning of DAA treatment, and 62 weeks from SVR. Patients who developed HCC were staged F3 (n = 1) and F4 (n = 3) at baseline, with one of them showing an increase and three a decrease in liver stiffness. Overall, patients who developed HCC showed a proportional median decrease in liver stiffness values of −13.6% as compared to a median decrease of −42.6% in patients who did not develop HCC.
| DISCUSSION
The advent of all-oral, interferon-free DAA therapy for chronic HCV infection has made possible treatment of a large number of patients with advanced liver disease and allowed assessment of modifications in disease stage and rate of development-or resolution-of complications of liver disease within a relatively short period of observation. As a fact, one European study carried out in patients on the liver transplant waiting list who were successfully treated with DAAs has shown that approximately one-third and one-fifth of patients, respectively, can be inactivated and delisted after a follow-up of 60 weeks, and a US study has shown that enlistment rate for decompensated liver disease due to HCV infection decreased by 30% in the DAAera. 14, 40 Other studies, carried out in patients with advanced cirrhosis and portal hypertension, have shown that obtaining a SVR to DAA treatment determines a meaningful reduction in hepatic venous pressure gradient, thus portending a future decrease in the development of complications of liver disease as well as an improvement in patients prognosis. 11, 12, 15 More recently, some studies carried out primarily in Eastern countries, with limited follow-up, and inclusion of heterogeneous cohorts of patients in terms of both disease severity and aetiology, consistently observed that even in HCV patients with less advanced liver disease, measurement of liver stiffness and assessment of other noninvasive indices of liver fibrosis tend to ameliorate in a relatively short-term follow-up after SVR. 16, 21 In the current study, our aim was to assess the modifications in liver stiffness, as an indirect measure of liver fibrosis, and of biochemical, noninvasive indices of liver disease severity (ie, APRI score, FIB-4 score) as well as of clinical and instrumental parameters suggestive of portal hypertension (ie, thrombocytopenia, splenomegaly) in a series of patients with advanced, compensated liver disease due to HCV infection who had obtained a SVR to DAA treatment and who had a follow-up after the end of treatment of at least 1 year. Under these conditions, we observed that obtaining a SVR is associated with a significant decrease in liver stiffness, as measured by transient elastography, and that although this decrease is proportionally more pronounced in cirrhotic patients as compared to patients with advanced fibrosis (−44.1% vs −36.4%), a decrease in at least one METAVIR stage-as assessed by liver stiffness measurement-is more frequently observed in F3 patients (76.0%) as compared to F4 patients (44.4%). Moreover, in our series, we found that absolute liver stiffness per se is quite a poor predictor of decrease in stiffness after at least 1-year follow-up, with an accuracy of baseline values below 60%. These results, accompanied by a consistent decrease in indirect indices of liver fibrosis such the APRI and FIB-4 scores, are in agreement with the findings of a recent systematic review and meta-analysis showing that the magnitude of decrease in liver stiffness after HCV clearance is greater in cirrhotic patient, while we feel that the only apparent contrasting result of a lower proportion of cirrhotic patients showing a METAVIR downstage as compared to F3 patients may be due to the fact that follow-up longer than 1 year might be needed in these patients to allow the observation of a larger proportion of downstaged patients. 41, 42 Considering the whole cohort, we found that liver stiffness decreased by approximately 40%, with at least some decrease in liver stiffness observed in more than 85% of patients, and with only 10% of patients showing an increase in liver stiffness despite having obtained viral eradication. As far as this latter issue is concerned, although none of the patients did develop liver decompensation during follow-up, four patients developed HCC and these patients showed a median decrease in liver stiffness of 13.6% as compared to a decrease of 42.6% in patients who did not develop this tumoural complication. We feel that drawing any definite conclusion on this topic on the basis of our data may be premature and that longer follow-up of larger cohorts is needed to confirm or confute these findings, yet we feel that patients who show a lack of decrease in liver stiffness after viral clearance may deserve particular attention, as in our series 20% of patients with this behaviour developed HCC during 1-year follow-up, and there is evidence showing that portal hypertension is an independent predictor of HCC development. 43 Moreover, our results are consistent with those very recently reported in a study with a similar follow-up (ie, 65.6 weeks after the end of successful DAA treatment) showing no liver-related events in 158 patients with F3 fibrosis, while 4.7% of the 317 patients with compensated cirrhosis had a liver-related event that included both decompensation and development of HCC; likewise, a very large study carried out in our Country, similar data showing that the actual rate of HCC may be reduced by means of DAA treatment, though a residual risk still exists. 44, 45 Previous studies assessing liver stiffness modifications after HCV eradication suggested that part of the improvement in liver stiffness values that are observed may be related to a decrease in liver necro-inflammatory activity, as heralded by decreased aminotransferases after viral clearance, rather than by an actual improvement in liver fibrosis. 16, 17 This suggestion is plausible, given the longer time necessary for fibrosis remodelling and the short-term follow-up of the majority of the studies carried out on this topic, and is also supported by the results of studies carried out with paired liver biopsy showing that histological findings compatible with cirrhosis are still present in approximately 40% of patients in a median time of 67 months after SVR, although even in patients who were still histologically classified as cirrhotics at follow-up the area of fibrosis assessed by morphometry was significantly, and dramatically, reduced. 46 In our study, we also observed that, using some well-established stiffness cut-offs, the proportion of patients with a liver stiffness indicative of the presence of clinically significant portal hypertension was almost halved (ie, from 25% to 13.5%) within 1-year follow-up after the end of successful antiviral treatment. 34, 35 Therefore, it well may be that the decrease in liver stiffness, which is consistently observed across studies after DAA-induced HCV clearance, may be a dynamic, multiphase event which is sustained by various mechanisms. In this regard, we found that in the follow-up period where we observed decreasing liver stiffness values, indices of liver necrosis and inflammation showed a rapid decrease and then a plateau, while indices of liver dysfunction such as serum albumin and bilirubin-though being generally preserved-as well as an indirect index of portal-systemic shunting such as gamma globulin, showed a constant improvement throughout the study period. 47 At the same time, median platelet counts and the proportion of patients with thrombocytopaenia significantly decreased and this finding was paralleled by a decrease in spleen bi-polar diameter as well as in the proportion of patients with splenomegaly. What can then be inferred by these data? It can be hypothesized that an initial decrease in liver stiffness after viral clearance may be secondary to the extinguishment of the necro-inflammatory process, while improvement in the biology of the modulable component of portal hypertension as well as liver fibrosis and architectural remodelling may occur later, thus being responsible for a further decrease in liver stiffness ( Figure S3 ). The rapid normalization of aminotransferases and the consistent improvement in liver function associated with amelioration of indirect indices of portal hypertension, such as splenomegaly and thrombocytopenia, may, in our opinion, well support this hypothesis. Lastly, our results are in keeping with those very recently obtained by Mauro et al 48 in
immune-suppressed patients with HCV recurrence after liver transplantation, who observed a clinically significant decrease in 62% of cirrhotic patients after SVR. This study undoubtedly has some drawbacks that need to be recognized: firstly, the lack of paired histology and/or of hepatic venous pressure gradient measurement at inclusion and at the end of follow-up does not allow to provide a more solid basis for the hypothesis put forward in our discussion, although in our time and age liver biopsy is seldom performed in HCV patients with instrumental evidence of cirrhosis, and portal pressure measurement is not commonly available in clinical practice; secondly, we did not assess modifications in more specific markers of liver fibrosis, such as the Enhanced Liver Fibrosis (ELF) score, nor did we assess whether the increase in platelet count might have been related to an improvement in the hepatic production of thrombopoietin rather than due to variations in portal pressure 49, 50 ; thirdly, modifications in liver stiffness can be considered soft end-points, as in patients with chronic HCV infection, there are no solid data showing that improvement in liver stiffness obtained by curing HCV infection is associated with hard end-points such as improved overall and liver-specific survival; lastly, although we followed up our cohort for one of the longest period after the end of DAA treatment available in the literature and our data are completely in agreement with the results of a recent meta-analysis showing that decreases in liver stiffness are greater in patients with cirrhosis, it may well be that even longer follow-up and larger cohorts of patients are needed so as to observe a meaningful shift in the occurrence of clinical events. 41 In conclusion, in this study, we observed that in patients with advanced, compensated chronic liver disease liver stiffness significantly improves after cure of HCV infection, and this improvement is accompanied by an amelioration of indirect indices of liver fibrosis and of liver function, and by a decrease in parameters suggestive of portal hypertension, although we feel that these initial and consistent data need to be confirmed in larger cohorts.
